TrialThe patient2022

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals.

Sarah-Jane Anderson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.